Consensus Outlook: Multiple Sclerosis
[Lowest Price Guaranteed: $4,995]
Published by FirstWord Pharma: 01 Dec 2013 | 68 | In Stock
Related Topics: Equity
Over the next five years, the global multiple sclerosis (MS) market is set to grow from .4 billion in 2012 to .3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
Multiple Sclerosis: On the cusp of a treatment revolution will allow you to
Forecast analysis report and data model
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters:
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.
Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.
Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.
Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.
Table of Contents
for Consensus Outlook: Multiple Sclerosis
1.Forecast Data Model (Excel)
1.1.Tabs: Market size
1.4.Mechanism of action
2.Forecast Analysis Report (PDF)
2.1. Contents: FirstWord Analysis Highlights
2.3.Multiple Sclerosis Marketplace
2.4.Key Multiple Sclerosis Developers
2.5.Multiple Sclerosis Class Dynamics
2.6.Tecfidera (dimethyl fumarate; Biogen) forecast
2.7.Aubagio (teriflunomide; Sanofi) forecast
2.8.Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
2.9.Tysabri (natalizumab; Biogen) forecast
2.10.Copaxone (glatiramer acetate; Teva) forecast
2.11.Avonex (interferon beta-1a; Biogen) forecast
2.12.Betaseron (interferon beta-1b; Bayer) forecast
2.13.Rebif (interferon beta-1a; Merck Serono) forecast
2.14.Extavia (interferon beta-1b; Novartis) forecast
2.15.Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
2.16.Laquinimod (Teva/Active Biotech) forecast
2.17.Daclizumab HYP (Biogen/AbbVie) forecast
2.18.Ocrelizumab (Biogen/Roche/Biogen) forecast
Number of Pages
|Title||Date Published||Price from||More Details|
|Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast|
Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales ForecastSummaryThis rep...
|30 Apr 2020 by Global Data||USD $495||More Info|
|Diabetes -- KOL Insight and Consensus Outlook Modules|
IntroductionThe medium term: battle lines are drawnThe fundamental drivers of the global diabetes ma...
|01 May 2014 by FirstWord Pharma||USD $7,900||More Info|
|Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook|
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
|20 Jan 2014 by FirstWord Pharma||USD $7,495||More Info|
|Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook|
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
|01 Dec 2013 by FirstWord Pharma||USD $4,995||More Info|
|Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top|
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
|01 Nov 2013 by FirstWord Pharma||USD $4,995||More Info|
|Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules|
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
|12 Mar 2013 by FirstWord Pharma||USD $7,495||More Info|
|HIV -- KOL Insight and Consensus Outlook Modules|
IntroductionWhat do frontline clinicians really think about current HIV treatment pathways and what ...
|24 Feb 2013 by FirstWord Pharma||USD $7,495||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.